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1. INTRODUCTION {#btm210143-sec-0001}
===============

The nanomedicine landscape continues to rapidly evolve driven by newly developed delivery strategies, new technologies, new treatment modalities, new drug approvals, and even clinical failures of current drugs. In 2016, we published a review article on the current clinical landscape of therapeutic nanoparticles, which highlighted over 25 Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved nanomedicines and over 45 other nanoparticle technologies that were not FDA/EMA approved but were currently being evaluated in ongoing clinical trials.[1](#btm210143-bib-0001){ref-type="ref"} That article also featured discussions on different nanoparticle types, their applications, their advantages as compared to free drugs, and their potential. We also discussed many of the biological issues (i.e., biodistribution, biological barrier breaching, and treating heterogeneous diseases), technological issues (i.e., scale‐up limitations, parameter optimization, and predicting efficacy), and clinical challenges that have limited the translation of nanoparticles.[1](#btm210143-bib-0001){ref-type="ref"} In these past 3 years, since that article was published, two intravenously administered nanoparticles have been FDA and EMA approved, one intratumorally administered nanoparticle received European market approval (CE Mark), over 75 new trials have begun for the previously highlighted nonapproved nanoparticles, and over 15 new nanoparticle technologies have entered clinical trials. In this 3‐year update, we highlight these new clinical approvals, trials, and technologies to provide an updated snapshot on the current clinical landscape of nanoparticles in 2019.

2. NEW APPROVALS {#btm210143-sec-0002}
================

Since our previous article, three nanomedicines have been approved: Patisiran/ONPATTRO, VYXEOS, and NBTXR3/Hensify. VYXEOS is a combination chemotherapy nanoparticle, developed and marketed by Jazz Pharmaceuticals that, encapsulates a synergistic molar ratio of cytarabine to daunorubicin of 5:1 and received FDA approval for the treatment of acute myeloid leukemia in August of 2017.[2](#btm210143-bib-0002){ref-type="ref"}, [3](#btm210143-bib-0003){ref-type="ref"} VYXEOS are 100 nm bilamellar liposomes where the lipid membrane consists of desaturated phosphatidylcholine:distearylphosphatidylglycerol:cholesterol (7:2:1M ratio).[4](#btm210143-bib-0004){ref-type="ref"} In the pivotal efficacy study (NCT01696084), VYXEOS provided a significant (*p* value = .005) improvement in overall survival of 9.6 months as compared to 5.9 months in the free drug control.[2](#btm210143-bib-0002){ref-type="ref"}, [5](#btm210143-bib-0005){ref-type="ref"} Importantly, this trial also showed that VYXEOS provided improved efficacy at a lower cumulative daunorubicin and cytarabine dose as compared to free drug counterparts.[6](#btm210143-bib-0006){ref-type="ref"} Since 2016, the number of clinical trials of VYXEOS has increased from 7 to 21 with the most recent trials investigating the use of VYXEOS in additional patient populations (e.g., children; NCT03826992) and leukemias (e.g., lymphoblastic leukemias; NCT03575325). Unlike other approved nanoparticles for cancer treatment, VYXEOS delivers two drugs in a synergistic ratio. Delivery of the synergistic combination of daunorubicin and cytarabine is enabled by the nanoparticle platform since the encapsulated ratio of drugs is able to both interact with target cells upon release. In the contrasting case of free drugs, each drug exhibits distinct pharmacokinetic profiles and are metabolized at different rates; as such, delivery of synergistic combinations of free drugs to target cells must also consider and counteract these biological processes. Product sales for VYXEOS were \$100.8 million in 2018.[7](#btm210143-bib-0007){ref-type="ref"} As the first clinically approved nanoparticle to deliver a synergistic combination of free drugs, VYXEOS can pave the way for new combination nanoparticle formulations that leverage widely‐utilized combination chemotherapy regimens from the clinic.[8](#btm210143-bib-0008){ref-type="ref"}, [9](#btm210143-bib-0009){ref-type="ref"}

Patisiran/ONPATTRO is an siRNA‐delivering lipid‐based nanoparticle developed and marketed by Alnylam, for the silencing of a specific gene responsible for expression of transthyretin, which can cause hereditary transthyretin amyloidosis.[10](#btm210143-bib-0010){ref-type="ref"} Patisiran/ONPATTRO lipid nanoparticles consist of (6Z,9Z,28Z,31Z)‐heptatriaconta‐6,9,28,31‐tetraen‐19‐yl‐4‐(dimethylamino) butanoate (DLin‐MC3‐DMA) plus cholesterol, 1,2‐distearoyl‐*sn*‐glycero‐3‐phosphocholine and α‐(3′‐{\[1,2‐di(myristyloxy)propanoxy\] carbonylamino}propyl)‐ω‐methoxy polyoxyethylene (PEG~2000~‐C‐DMG).[11](#btm210143-bib-0011){ref-type="ref"} Patisiran/ONPATTRO was approved by the FDA in August of 2018[12](#btm210143-bib-0012){ref-type="ref"} and was the first clinically approved example of an RNAi therapy‐delivering nanoparticle administered intravenously. Importantly, Patisiran/ONPATTRO is also the first FDA approved RNAi therapeutic in general,[12](#btm210143-bib-0012){ref-type="ref"} independent of the nanoparticle delivery vehicle. Approval of the first RNAi therapeutic was a major milestone in the biotech industry and considering that the delivery vehicle was a nanoparticle, approval of Patisiran/ONPATTRO was also a major milestone for nanomedicines. In the Phase III efficacy study (NCT01960348), 56% of patients receiving Patisiran/ONPATTRO exhibited improvements in modified Neuropathy Impairment Score+7 as compared to 4% receiving the placebo.[10](#btm210143-bib-0010){ref-type="ref"} Moreover, serum transthyretin decreased by over 70% in patients receiving Patisiran/ONPATTRO as compared to less than 20% in patients receiving the placebo.[10](#btm210143-bib-0010){ref-type="ref"} Global net revenues for Patisiran/ONPATTRO were \$12.1 million in 2018 with over 200 patients in Europe and the United States receiving treatment.[13](#btm210143-bib-0013){ref-type="ref"} As the first clinically approved siRNA/RNAi therapeutic, Patisiran/ONPATTRO demonstrates how nanoparticles can be used to enable the delivery, and in this case approval, of highly challenging therapeutics to humans.

NBTXR3/Hensify is a 50 nm crystalline hafnium oxide nanoparticle with negatively charged phosphate coating, developed and marketed by Nanobiotix.[14](#btm210143-bib-0014){ref-type="ref"} NBTXR3/Hensify enhances external radiotherapy via a physical mode of action that relies on hafnium\'s natural radioenhancing properties.[14](#btm210143-bib-0014){ref-type="ref"}, [15](#btm210143-bib-0015){ref-type="ref"} Specifically, the interaction between ionizing radiation and hafnium facilitates a higher energy deposit as compared to ionizing radiation without hafnium interaction; this results in the generation of significantly more electrons and increases radiation‐mediated cell death from standard radiation oncology procedures.[14](#btm210143-bib-0014){ref-type="ref"}, [15](#btm210143-bib-0015){ref-type="ref"} NBTXR3/Hensify received CE Mark approval in April of 2019 for the treatment of locally advanced soft tissue sarcoma.[16](#btm210143-bib-0016){ref-type="ref"} Since our previous article, the number of clinical trials of NBTXR3/Hensify has increased from 1 to 8. While NBTXR3/Hensify is approved for intratumoral administration, clinical trials had investigated it for intra‐arterial administration (NCT01946867). The newest trials are only investigating NBTXR3/Hensify for intratumoral injections, but have expanded their indications to include treatment of prostate cancer (NCT02805894) and lung cancer with combined immunotherapy (NCT03589339). The reasoning for including immunotherapy with NBTXR3/Hensify treatment builds on preclinical data that demonstrated improved efficacy of immunotherapies following NBTXR3/Hensify treatment, stemming from an increased antitumor immune response.[17](#btm210143-bib-0017){ref-type="ref"}, [18](#btm210143-bib-0018){ref-type="ref"} Since the mechanism of action of NBTXR3/Hensify is unique and unlike other approved nanoparticles or therapeutics, NBTXR3/Hensify may represent the next‐generation of nanoparticle therapeutics; specifically, nanoparticle therapeutics that can provide therapeutic benefits in a complementary and possibly synergistic way to standard therapeutic modalities. Table [1](#btm210143-tbl-0001){ref-type="table"}, which previously listed FDA/EMA approved nanomedicines as of 2016, is now updated to include these recently approved nanoparticles.

###### 

Updated clinically approved nanoparticle therapies and diagnostics, grouped by their broad indication

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                                      Particle type/drug                                                                                                   Approved application/indication                                                                                                   Approval (year)             Investigated application/indication                                                                                                                                       Updates on number of studies on [ClinicalTrials.gov](https://ClinicalTrials.gov) identifier
  ----------------------------------------- -------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- --------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  New approvals since 2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  VYXEOS\                                   Liposomal formulation of cytarabine:daunorubicin (5:1M ratio)                                                        Acute myeloid leukemia                                                                                                            FDA (2017)\                 Various leukemias                                                                                                                                                         2016:\
  CPX‐351\                                                                                                                                                                                                                                                                                         EMA (2018)                                                                                                                                                                                            VYXEOS: 7\
  (Jazz Pharmaceuticals)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         VYXEOS: 21

  ONPATTRO\                                 Lipid nanoparticle RNAi for the knockdown of disease‐causing TTR protein                                             Transthyretin (TTR)‐mediated amyloidosis                                                                                          FDA (2018)\                 Transthyretin (TTR)‐mediated amyloidosis                                                                                                                                  2016:\
  Patisiran\                                                                                                                                                                                                                                                                                       EMA (2018)                                                                                                                                                                                            3\
  ALN‐TTR02 (Alnylam Pharmaceuticals)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         11

  NBTXR3\                                   Hafnium oxide nanoparticles stimulated with external radiation to enhance tumor cell death via electron production   Locally advanced squamous cell carcinoma                                                                                          CE Mark (2019)              Locally advanced soft tissue sarcoma                                                                                                                                      2016:\
  Hensify\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1 (an additional trial was listed as completed at the time)\
  (Nanobiotix)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         8

  Cancer nanoparticle medicines                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Doxil\                                    Liposomal doxorubicin (PEGylated)                                                                                    Ovarian cancer (secondary to platinum based therapies)\                                                                           FDA (1995)\                 Various cancers including: solid malignancies, ovarian, breast, leukemia, lymphomas, prostate, metastatic, or liver                                                       2016:\
  Caelyx\                                                                                                                                                        HIV‐associated Kaposi\'s sarcoma (secondary to chemotherapy)\                                                                     EMA (1996)                                                                                                                                                                                            Doxil: 166\
  (Janssen)                                                                                                                                                      Multiple myeloma (secondary)                                                                                                                                                                                                                                                                                                            CAELYX: 90\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Doxil: 182\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         CAELYX: 109

  DaunoXome\                                Liposomal daunorubicin (non‐PEGylated)                                                                               HIV‐associated Kaposi\'s sarcoma (primary)                                                                                        FDA (1996)                  Various leukemias                                                                                                                                                         2016:\
  (Galen)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                DaunoXome: 32\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         DaunoXome: 15

  Myocet\                                   Liposomal doxorubicin (non‐PEGylated)                                                                                Treatment of metastatic breast cancer (primary)                                                                                   EMA (2000)                  Various cancers including: breast, lymphoma, or ovarian                                                                                                                   2016:\
  (Teva UK)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Myocet: 32\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Myocet: 35

  Abraxane\                                 Albumin‐particle bound paclitaxel                                                                                    Advanced non‐small cell lung cancer (surgery or radiation is not an option)\                                                      FDA (2005)\                 Various cancers including: solid malignancies, breast, lymphomas, bladder, lung, pancreatic, head and neck, prostate, melanoma, or liver                                  2016:\
  (Celgene)                                                                                                                                                      Metastatic breast cancer (secondary)\                                                                                             EMA (2008)                                                                                                                                                                                            Abraxane: 295\
                                                                                                                                                                 Metastatic pancreatic cancer (primary)                                                                                                                                                                                                                                                                                                  2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Abraxane: 432

  Marqibo\                                  Liposomal vincristine\                                                                                               Philadelphia chromosome‐negative acute lymphoblastic leukemia (tertiary)                                                          FDA (2012)                  Various cancers including: lymphoma, brain, leukemia, or melanoma                                                                                                         2016:\
  (Spectrum)                                (non‐PEGylated)                                                                                                                                                                                                                                                                                                                                                                                                                                              Marqibo: 23\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Marqibo: 28

  MEPACT\                                   Liposomal mifamurtide\                                                                                               Treatment for osteosarcoma (primary following surgery)                                                                            EMA (2009)                  Osteosarcomas                                                                                                                                                             2016:\
  (Millennium)                              (non‐PEGylated)                                                                                                                                                                                                                                                                                                                                                                                                                                              MEPACT: 4 (3 active/recruiting)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         MEPACT: 9 (3 active/recruiting)

  Onivyde\                                  Liposomal irinotecan\                                                                                                Metastatic pancreatic cancer (secondary)                                                                                          FDA (2015)                  Various cancers including: solid malignancies, breast, pancreatic, sarcomas, or brain                                                                                     2016:\
  MM‐398\                                   (PEGylated)                                                                                                                                                                                                                                                                                                                                                                                                                                                  MM‐398/Onivyde: 7 (6 active/recruiting)\
  (Merrimack)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         MM‐398/Onivyde: 38 (26 active/recruiting)

  Iron‐replacement nanoparticle therapies                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  CosmoFer\                                 Iron dextran colloid                                                                                                 Iron deficient anemia                                                                                                             FDA (1992)\                 Iron deficient anemia                                                                                                                                                     2016:\
  INFeD\                                                                                                                                                                                                                                                                                           Some of Europe                                                                                                                                                                                        INFeD: 6 (1 recruiting)\
  Ferrisat\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              2019:\
  (Pharmacosmos)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         INFeD: 9

  DexFerrum\                                Iron dextran colloid                                                                                                 Iron deficient anemia                                                                                                             FDA (1996)                  Iron deficient anemia                                                                                                                                                     2016:\
  DexIron\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               DexFerrum: 6\
  (American Regent)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         DexFerrum: 9

  Ferrlecit\                                Iron gluconate colloid                                                                                               Iron replacement for anemia treatment in patients with chronic kidney disease                                                     FDA (1999)                  Iron deficient anemia                                                                                                                                                     2016:\
  (Sanofi)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Ferrlecit: 13 (2 recruiting)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Ferrlecit: 20 (0 recruiting)

  Venofer\                                  Iron sucrose colloid                                                                                                 Iron replacement for anemia treatment in patients with chronic kidney disease                                                     FDA (2000)                  Iron deficient anemia\                                                                                                                                                    2016:\
  (American Regent)                                                                                                                                                                                                                                                                                                            Following autologous stem cell transplantation                                                                                                                            Venofer: 44\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Venofer: 60

  Feraheme\                                 Iron polyglucose sorbitol carboxymethylether colloid                                                                 Iron deficiency in patients with chronic kidney disease                                                                           FDA (2009)                  Iron deficient anemia\                                                                                                                                                    2016:\
  (AMAG)\                                                                                                                                                                                                                                                                                                                      Imaging: brain metastases, lymph node metastases, neuroinflammation in epilepsy, head and neck cancer, myocardial infarction, or multiple sclerosis                       Ferumoxytol: 57 (6 recruiting/active for anemia treatment; 22 recruiting/active for imaging applications)\
  Rienso\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                2019:\
  (Takeda)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Ferumoxytol: 84 (6 recruiting/active for anemia treatment; 22 recruiting/active for imaging applications)
  Ferumoxytol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Injectafer\                               Iron carboxymaltose colloid                                                                                          Iron deficient anemia                                                                                                             FDA (2013)                  Iron deficient anemia                                                                                                                                                     2016:\
  Ferinject\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Ferinject: 50\
  (Vifor)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Injectafer: 8\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Ferinject: 79\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Injectafer: 24

  Monofer\                                  10% iron isomaltoside 1,000 colloid                                                                                  Treating iron deficiency and anemia when oral methods do not work or when iron delivery is required immediately                   Some of Europe              Iron deficient anemia                                                                                                                                                     2016:\
  (Pharmacosmos)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Monofer: 22 (3 active/recruiting)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Monofer: 22 (11 active/recruiting)

  Diafer\                                   5% iron isomaltoside 1,000 colloid                                                                                   Iron deficient anemia                                                                                                             Some of Europe              Iron deficient anemia                                                                                                                                                     2016:\
  (Pharmacosmos)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Diafer: 1 recruiting\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Diafer: 1 completed

  Nano/microparticle imaging agents                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Definity\                                 Perflutren lipid microspheres                                                                                        Ultrasound contrast agent                                                                                                         FDA (2001)                  Ultrasound enhancement for: liver or breast or intraocular or pancreatic tumors, pulmonary diseases, heart function, transcranial injuries, strokes, or liver cirrhosis   2016:\
  (Lantheus Medical Imaging)                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Definity: 58\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Definity: 87

  Feridex I.V.\                             Iron dextran colloid                                                                                                 Imaging of liver lesions                                                                                                          FDA (1996)\                 N/A: No current studies                                                                                                                                                   2016:\
  (AMAG)\                                                                                                                                                                                                                                                                                          Discontinued (2008)                                                                                                                                                                                   Endorem: 4\
  Endorem                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Feridex: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         No current active or recruiting studies\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Endorem: 4\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Feridex: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         No current active or recruiting studies

  Optison\                                  Human serum albumin stabilized perflutren microspheres                                                               Ultrasound contrast agent                                                                                                         FDA (1997)\                 Ultrasound enhancement for: lymph node, renal cell carcinoma, myocardial infarction, pulmonary transit times, or heart transplant rejections                              2016:\
  (GE Healthcare)                                                                                                                                                                                                                                                                                  EMA (1998)                                                                                                                                                                                            Optison: 11 currently active or recruiting studies\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Optison: 30 (6 active)

  SonoVue\                                  Phospholipid stabilized microbubble                                                                                  Ultrasound contrast agent                                                                                                         EMA (2001)                  Ultrasound enhancement for: liver neoplasms, prostate or breast or pancreatic cancer, or coronary/pulmonary disease                                                       2016:\
  (Bracco Imaging)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       SonoVue: 43\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         SonoVue: 72

  Resovist\                                 Iron carboxydextran colloid                                                                                          Imaging of liver lesions                                                                                                          Some of Europe\             N/A\                                                                                                                                                                      2016:\
  (Bayer Schering Pharma)\                                                                                                                                                                                                                                                                         Discontinued (2009)         No current studies                                                                                                                                                        2 studies mention Resovist:\
  Cliavist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               No current active or recruiting studies\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2 studies mention Resovist:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         No current active or recruiting studies

  Ferumoxtran‐10 Combidex\                  Iron dextran colloid                                                                                                 Imaging lymph node metastases                                                                                                     Only available in Holland   Imaging lymph node metastases                                                                                                                                             2016:\
  Sinerem\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Ferumoxtran‐10:11 (1 active)\
  (AMAG)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Ferumoxtran‐10:24 (1 active; 6 recruiting)

  Nanoparticle vaccines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Epaxal\                                   Liposome with hepatitis A virus                                                                                      Hepatitis A vaccine                                                                                                               Some of Europe\             Safety and immunogenicity of hepatitis A vaccine                                                                                                                          2016:\
  (Crucell)                                                                                                                                                                                                                                                                                        (discontinued)                                                                                                                                                                                        Epaxal: 6 (1 recruiting)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Epaxal: 6 (0 recruiting)

  Inflexal V\                               Liposome with trivalent‐influenza                                                                                    Influenza vaccine                                                                                                                 Some of Europe\             Safety and immunogenicity of influenza vaccine                                                                                                                            2016:\
  (Crucell)                                                                                                                                                                                                                                                                                        (discontinued)                                                                                                                                                                                        Inflexal V: 14 (all completed)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Inflexal V: 14 (all completed)

  Particle anesthetics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Diprivan                                  Liposomal propofol                                                                                                   Induction and maintenance of sedation or anesthesia                                                                               FDA (1989)                  General anesthesia in specific situations: morbidly obese patients, open heart surgery, or spinal surgery                                                                 2016:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Diprivan: 110\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2016:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Diprivan: 162

  Nanoparticles for fungal treatments                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  AmBisome\                                 Liposomal amphotericin B                                                                                             Cryptococcal meningitis in HIV‐infected patients\                                                                                 FDA (1997)\                 Preventing or treating invasive fungal infections                                                                                                                         2016:\
  (Gilead Sciences)                                                                                                                                              Aspergillus, Candida and/or Cryptococcus species infections (secondary)\                                                          Most of Europe                                                                                                                                                                                        AmBisome: 50\
                                                                                                                                                                 Visceral leishmaniasis parasite in immunocompromised patients                                                                                                                                                                                                                                                                           2019:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         AmBisome: 57

  Nanoparticles for macular degeneration                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Visudyne\                                 Liposomal verteporfin                                                                                                Treatment of subfoveal choroidal neovascularization from age‐related macular degeneration, pathologic, or ocular histoplasmosis   FDA (2000)\                 Macular degeneration                                                                                                                                                      2016:\
  (Bausch and Lomb)                                                                                                                                                                                                                                                                                EMA (2000)                                                                                                                                                                                            Visudyne: 52\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2016:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Visudyne: 60
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note*: Newly approved nanoparticles are separately listed in the first rows. Modified with permission from Reference [1](#btm210143-bib-0001){ref-type="ref"}.

Abbreviations: EMA, European Medicines Agency; FDA, Food and Drug Administration.

3. UPDATE ON PREVIOUS TRIALS {#btm210143-sec-0003}
============================

In our previous article, over 45 different nonapproved nanoparticles (liposomes, polymeric, micelles, albumin‐bound nanoparticles, and inorganic nanoparticles) were listed as active in a total of over 80 different clinical trials (mostly for the treatment of various cancers but also radiation exposure, arthritis, pneumonia, amyloidosis, hepatitis, and fibrosis). Of these 80 trials, 28 have since been completed with 12 being terminated early. Of the 45 different nanoparticles, seven possessed targeting functionality, and six offered stimuli‐responsive functions (e.g., thermal ablation in response to near‐infrared light, thermosensitive liposomes). Three of these nanoparticles, as mentioned above, have received FDA, EMA, or CE Mark approval. Here, we have updated our previous table to reflect the current status of each of these technologies to include new clinical trials and updates on previous trials. Seventy‐five new trials exist for the previously highlighted nanoparticles. Of these 75 new trials, 14 are for VYXEOS, 8 are for Patisiran/ONPATTRO, and 6 are for NBTXR3/Hensify. Of particular note, CRLX101, a cyclodextrin‐based nanoparticle‐camptothecin conjugate, began nine new trials and ABI‐009, albumin bound rapamycin, began 12 new trials. Table [2](#btm210143-tbl-0002){ref-type="table"} summarizes these findings and additionally provides technical and clinical updates, when publicly available, for these clinically investigated nanoparticles.

###### 

Updates on previously reported intravenous nanoparticle clinical trials that have not been clinically approved and are currently undergoing clinical trials (not yet recruiting, recruiting, or active)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name (company)                                        Particle type/drug                                                                                                   Investigated application/indication                                                                                                   [ClinicalTrials.gov](https://ClinicalTrials.gov) identifiers (phase)                                                       Updates since 2016
  ----------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Liposomes (cancer)                                                                                                                                                                                                                                                                                                                                                                                                                          

  PROMITIL\                                             PEGylated liposomal mitomycin‐C                                                                                      Solid tumors                                                                                                                          2016:\                                                                                                                     1 new trial\
  (Lipomedix Pharmaceuticals)                                                                                                                                                                                                                                                                                      NCT01705002 (Ph I): Completed\                                                                                             1 trial completed
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03823989 (Ph Ib): Recruiting                                                                                            

  ThermoDox®\                                           Lyso‐thermosensitive liposomal doxorubicin                                                                           Temperature‐triggered doxorubicin release:\                                                                                           2016:\                                                                                                                     1 new trial\
  (Celsion)                                                                                                                                                                  Breast cancer recurrence at chest wall (microwave hypothermia)\                                                                       NCT02536183 (Ph I): Recruiting\                                                                                            3 trials completed\
                                                                                                                                                                             Hepatocellular carcinoma (radiofrequency ablation)\                                                                                   NCT00826085 (Ph I/II): Completed\                                                                                          NCT02181075 (Ph I): Published results highlight how ThermoDox in combination with externally induced mild hyperthermia increase intratumoral concentration of dox by 3.7 times as compared to ThermoDox without hyperthermia induction.[26](#btm210143-bib-0026){ref-type="ref"}
                                                                                                                                                                             Liver tumors (mild hypothermia)\                                                                                                      NCT02112656 (Ph III): Completed\                                                                                           
                                                                                                                                                                             Refractory solid tumors (magnetic resonance high intensity focused ultrasound)                                                        NCT02181075 (Ph I): Completed\                                                                                             
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03749850 (Ph I): Not yet recruiting                                                                                     

  VYXEOS\                                               Liposomal formulation of cytarabine:daunorubicin (5:1M ratio)                                                        Leukemias                                                                                                                             2016:\                                                                                                                     Received FDA approval in 2017 and EMA approval in 2018\
  CPX‐351\                                                                                                                                                                                                                                                                                                         NCT01804101 (not provided)\                                                                                                13 new trials
  (Celator Pharmaceuticals)                                                                                                                                                                                                                                                                                        NCT02286726 (Ph II)\                                                                                                       
                                                                                                                                                                                                                                                                                                                   NCT02019069 (Ph II)\                                                                                                       
                                                                                                                                                                                                                                                                                                                   NCT01943682 (Ph I)\                                                                                                        
                                                                                                                                                                                                                                                                                                                   NCT02269579 (Ph II)\                                                                                                       
                                                                                                                                                                                                                                                                                                                   NCT02533115 (Ph IV)\                                                                                                       
                                                                                                                                                                                                                                                                                                                   NCT01696084 (Ph III)\                                                                                                      
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   21 Total studies                                                                                                           

  Oncoprex\                                             FUS1 (TUSC2) encapsulated liposome                                                                                   Lung cancer                                                                                                                           2016:\                                                                                                                     0 new trials
  (Genprex)                                                                                                                                                                                                                                                                                                        NCT01455389 (Ph I/II): Active, not recruiting                                                                              

  Halaven\                                              Liposomal eribulin mesylate                                                                                          Solid tumors                                                                                                                          2016:\                                                                                                                     1 new trial\
  E7389‐LF\                                                                                                                                                                                                                                                                                                        NCT01945710 (Ph I): Completed\                                                                                             1 trial completed
  (Eisai)                                                                                                                                                                                                                                                                                                          2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03207672 (Ph I): Recruiting                                                                                             

  ^188^Re‐BMEDA‐liposome                                ^188^Re‐N,N‐bis (2‐mercaptoethyl)‐N′,N′‐diethylethylenediamine pegylated liposome                                    Advanced solid tumors                                                                                                                 2016:\                                                                                                                     0 new trials
                                                                                                                                                                                                                                                                                                                   NCT02271516 (Ph I): Unknown                                                                                                

  Mitoxantrone hydrochloride liposome\                  Mitoxantrone liposome                                                                                                Lymphoma and breast cancer                                                                                                            2016:\                                                                                                                     1 new trial\
  (CSPC ZhongQi Pharmaceutical Technology)                                                                                                                                                                                                                                                                         NCT02131688 (Ph I): Unknown\                                                                                               1 trial withdrawn\
                                                                                                                                                                                                                                                                                                                   NCT02596373 (Ph II): Recruiting\                                                                                           1 trial terminated
                                                                                                                                                                                                                                                                                                                   NCT02597387 (Ph II): Recruiting\                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT02595242 (Ph I): Withdrawn\                                                                                             
                                                                                                                                                                                                                                                                                                                   NCT02597153 (Ph II): Terminated (only one subject enrolled in 1.5 years)\                                                  
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03776279 (Ph I): Recruiting                                                                                             

  JVRS‐100                                              Cationic liposome incorporating plasmid DNA complex for immune system stimulation                                    Leukemia                                                                                                                              2016:\                                                                                                                     0 new trials\
                                                                                                                                                                                                                                                                                                                   NCT00860522 (Ph I): Completed                                                                                              1 trial completed

  Lipocurc\                                             Liposomal curcumin                                                                                                   Solid tumors                                                                                                                          2016:\                                                                                                                     0 new trials\
  (SignPath Pharma)                                                                                                                                                                                                                                                                                                NCT02138955 (Ph I/II): Unknown                                                                                             1 trial changed to unknown status

  LiPlaCis\                                             Liposomal formulated cisplatin with specific degradation‐controlled drug release via phospholipase A2 (PLA2)         Advanced or refractory tumors                                                                                                         2016:\                                                                                                                     0 new trials
  (LiPlasome Pharma)                                                                                                                                                                                                                                                                                               NCT01861496 (Ph I): Recruiting                                                                                             

  MM‐302\                                               HER2‐targeted liposomal doxorubicin (PEGylated)                                                                      Breast cancer                                                                                                                         2016:\                                                                                                                     1 new trial that was withdrawn\
  (Merrimack Pharmaceuticals)                                                                                                                                                                                                                                                                                      NCT01304797 (Ph I): Unknown\                                                                                               1 trial terminated\
                                                                                                                                                                                                                                                                                                                   NCT02213744 (Ph II/III): Terminated (felt not to show benefit over control per DMC and confirmed via futility analysis)\   1 trial changed to unknown status\
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           Merrimack halted the phase II study of MM‐302 (NCT02213744) due to it being unlikely that MM‐302 would demonstrate benefits over the control comparison.[27](#btm210143-bib-0027){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                   NCT02735798 (Ph I): Withdrawn (the study was not started due to the sponsor choosing to not fund the trial)                Merrimack published results for NCT01304797 where data suggested that a tracer nanoparticle could be used to select for patients that exhibit enhanced EPR effect as a means to screen for patients who would likely respond favorably to nanomedicines.[28](#btm210143-bib-0028){ref-type="ref"}

  LIPUSU®\                                              Paclitaxel liposome                                                                                                  Advanced solid tumors, or gastric, breast cancer                                                                                      2016:\                                                                                                                     1 new trial
  (Nanjing Luye Sike Pharmaceutical Co., Ltd.)                                                                                                                                                                                                                                                                     NCT01994031 (Ph IV): Unknown\                                                                                              
                                                                                                                                                                                                                                                                                                                   NCT02142790 (Ph IV): Unknown\                                                                                              
                                                                                                                                                                                                                                                                                                                   NCT02163291 (Ph II): Unknown\                                                                                              
                                                                                                                                                                                                                                                                                                                   NCT02142010 (not provided): Unknown\                                                                                       
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT02996214 (Ph IV): Not yet recruiting                                                                                    

  Liposomes (gene therapy: Cancer)                                                                                                                                                                                                                                                                                                                                                                                                            

  TKM‐080301\                                           Lipid particle targeting polo‐like kinase 1 (PLK1) for delivery of siRNA                                             Hepatocellular carcinoma                                                                                                              2016:\                                                                                                                     0 new trials\
  (Arbutus Biopharma)                                                                                                                                                                                                                                                                                              NCT02191878 (Ph I/II): Completed                                                                                           1 trial completed

  siRNA‐EphA2‐DOPC                                      siRNA liposome for EphA2 knockdown                                                                                   Solid tumors                                                                                                                          2016:\                                                                                                                     0 new trials
                                                                                                                                                                                                                                                                                                                   NCT01591356 (Ph I): Recruiting                                                                                             

  PNT2258\                                              Proprietary single‐stranded DNAi (PNT100) encapsulated in lipid nanoparticles                                        Lymphomas                                                                                                                             2016:\                                                                                                                     0 new trials\
  (ProNAi Therapeutics)                                                                                                                                                                                                                                                                                            NCT02378038 (Ph II): Terminated\                                                                                           1 trial completed\
                                                                                                                                                                                                                                                                                                                   NCT02226965 (Ph II): Unknown\                                                                                              1 trial terminated\
                                                                                                                                                                                                                                                                                                                   NCT01733238 (Ph II): Completed                                                                                             1 trial changed to unknown status

  BP1001\                                               Growth factor receptor bound protein‐2 (Grb‐2) antisense oligonucleotide encapsulated in neutral liposomes           Leukemias                                                                                                                             2016:\                                                                                                                     2 new trials
  (Bio‐Path Holdings)                                                                                                                                                                                                                                                                                              NCT01159028 (Ph I): Active, not recruiting\                                                                                
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT02923986 (Ph I): Recruiting\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT02781883 (Ph II): Recruiting                                                                                            

  DCR‐MYC\                                              DsiRNA lipid nanoparticle for NYC oncogene silencing                                                                 Solid tumors, multiple myeloma, lymphoma, or hepatocellular carcinoma                                                                 2016:\                                                                                                                     0 new trials\
  (Dicerna Pharmaceuticals)                                                                                                                                                                                                                                                                                        NCT02110563 (Ph I): Terminated (sponsor decision)\                                                                         2 trials terminated\
                                                                                                                                                                                                                                                                                                                   NCT02314052 (Ph I/II) terminated (sponsor decision)                                                                        DCR‐MYC development discontinued.[29](#btm210143-bib-0029){ref-type="ref"}

  Atu027\                                               AtuRNAi liposomal formulation for PKN3 knockdown in vascular endothelium                                             Pancreatic cancer                                                                                                                     2016:\                                                                                                                     0 new trials\
  (Silence Therapeutics GmbH)                                                                                                                                                                                                                                                                                      NCT01808638 (Ph I/II): Completed                                                                                           1 trial completed

  SGT‐53\                                               Cationic liposome with anti‐transferrin receptor antibody, encapsulating wildtype p53 sequence                       Glioblastoma, solid tumors, or pancreatic cancer                                                                                      2016:\                                                                                                                     1 new trial\
  (SynerGene Therapeutics)                                                                                                                                                                                                                                                                                         NCT02354547 (Ph I): Recruiting\                                                                                            1 trial completed
                                                                                                                                                                                                                                                                                                                   NCT02354547 (Ph I): Recruiting\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT02340156 (Ph II): Recruiting\                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT00470613 (Ph I): Completed\                                                                                             
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03554707 (Ph I): Not yet recruiting                                                                                     

  SGT‐94\                                               RB94 plasmid DNA in a liposome with anti‐transferrin receptor antibody                                               Solid tumors                                                                                                                          2016:\                                                                                                                     0 new trials\
  (SynerGene Therapeutics)                                                                                                                                                                                                                                                                                         NCT01517464 (Ph I): Completed                                                                                              1 trial completed

  MRX34\                                                Double‐stranded RNA mimic of miR‐34 encapsulated in liposomes                                                        Liver cancer                                                                                                                          2016:\                                                                                                                     1 new trial that was withdrawn\
  (Mirna Therapeutics)                                                                                                                                                                                                                                                                                             NCT01829971 (Ph I): Terminated (five immune related serious adverse events)\                                               1 trial terminated
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT02862145 (Ph I): Withdrawn (5 immune related serious adverse events in phase 1 study)                                   

  TargomiRs\                                            Anti‐EGFR bispecific antibody minicells (bacteria derived nanoparticles) with a miR‐16 based microRNA payload        Mesothelioma and non‐small cell lung cancer                                                                                           2016:\                                                                                                                     0 new trials\
  (EnGeneIC)                                                                                                                                                                                                                                                                                                       NCT02369198 (Ph I): Completed                                                                                              1 trial completed\
                                                                                                                                                                                                                                                                                                                                                                                                                                              NCT02369198 (Ph I): Published study demonstrates that TargomiRs were well‐tolerated by refractory malignant pleural mesothelioma patients.[30](#btm210143-bib-0030){ref-type="ref"}

  Liposomes (gene therapy: Other)                                                                                                                                                                                                                                                                                                                                                                                                             

  ND‐L02‐s0201\                                         siRNA lipid nanoparticle conjugated to vitamin A                                                                     Hepatic fibrosis and pulmonary fibrosis                                                                                               2016:\                                                                                                                     3 new trials (2 completed)\
  (Nitto Denko)                                                                                                                                                                                                                                                                                                    NCT02227459 (Ph I): Completed\                                                                                             1 trial completed
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT01858935 (Ph I): Completed\                                                                                             
                                                                                                                                                                                                                                                                                                                   NCT03241264 (Ph I): Completed\                                                                                             
                                                                                                                                                                                                                                                                                                                   NCT03538301 (Ph II): Recruiting                                                                                            

  ARB‐001467\                                           Lipid particle containing three RNAi therapeutics that target three sites on the HBV genome                          Hepatitis B                                                                                                                           2016:\                                                                                                                     0 new trials\
  TKM‐HBV\                                                                                                                                                                                                                                                                                                         NCT02631096 (Ph II): Completed                                                                                             1 trial completed
  (Arbutus Biopharma)                                                                                                                                                                                                                                                                                                                                                                                                                         

  ONPATTRO\                                             Lipid nanoparticle RNAi for the knockdown of disease‐causing TTR protein                                             Transthyretin (TTR)‐mediated amyloidosis                                                                                              2016:\                                                                                                                     Received FDA and EMA approval in 2018
  Patisiran\                                                                                                                                                                                                                                                                                                       NCT02510261 (Ph III)\                                                                                                      
  ALN‐TTR02 (Alnylam Pharmaceuticals)                                                                                                                                                                                                                                                                              NCT01961921 (Ph II)\                                                                                                       
                                                                                                                                                                                                                                                                                                                   NCT01960348 (Ph III)\                                                                                                      
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   11 total studies                                                                                                           

  Liposomes (other)                                                                                                                                                                                                                                                                                                                                                                                                                           

  CAL02\                                                Sphingomyelin and cholesterol liposomes for toxin neutralization                                                     Pneumonia                                                                                                                             2016:\                                                                                                                     0 new trials\
  (Combioxin SA)                                                                                                                                                                                                                                                                                                   NCT02583373 (Ph I): Completed                                                                                              1 trial completed

  Nanocort\                                             Liposomal prednisolone (PEGylated)                                                                                   Rheumatoid arthritis and hemodialysis fistula maturation                                                                              2016:\                                                                                                                     0 new trials\
  (Enceladus in collaboration with sun pharma global)                                                                                                                                                                                                                                                              NCT02495662 (Ph II): Terminated (slow inclusion)\                                                                          2 trials terminated
                                                                                                                                                                                                                                                                                                                   NCT02534896 (Ph III): Terminated                                                                                           

  RGI‐2001\                                             Liposomal formulaton of α‐GalCer                                                                                     Mitigating graft versus host disease following stem cell transplant                                                                   2016:\                                                                                                                     1 new trial
  (Regimmune)                                                                                                                                                                                                                                                                                                      NCT01379209 (Ph I/II): Unknown\                                                                                            
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT04014790 (Ph II): Not yet recruiting                                                                                    

  Sonazoid                                              F‐butane encapsulated in a lipid shell                                                                               Contrast enhanced ultrasound for imaging hepatocellular carcinoma, skeletal muscle perfusion, or for estimating portal hypertension   2016:\                                                                                                                     0 new trials\
                                                                                                                                                                                                                                                                                                                   NCT00822991 (not provided): Recruiting\                                                                                    1 trial changed to unknown status\
                                                                                                                                                                                                                                                                                                                   NCT02398266 (Ph II): Unknown\                                                                                              1 trial completed
                                                                                                                                                                                                                                                                                                                   NCT02188901 (not provided): Completed\                                                                                     
                                                                                                                                                                                                                                                                                                                   NCT02489045 (Ph IV): Recruiting                                                                                            

  Polymeric and micelles (cancer)                                                                                                                                                                                                                                                                                                                                                                                                             

  AZD2811\                                              Aurora B kinase inhibitor in BIND therapeutics polymer particle accurin platform                                     Advanced solid tumors                                                                                                                 2016:\                                                                                                                     2 new trials (1 terminated)
  (AstraZeneca with BIND Therapeutics)                                                                                                                                                                                                                                                                             NCT02579226 (Ph I): Recruiting\                                                                                            
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03366675 (Ph II): Terminated (early detection of the purpose of the study)\                                             
                                                                                                                                                                                                                                                                                                                   NCT03217838 (Ph I): New, recruiting                                                                                        

  BIND‐014\                                             PSMA targeted (via ACUPA) docetaxel PEG‐PLGA or PLA--PEG particle                                                    Prostate, metastatic, non‐small cell lung, cervical, head and neck, or KRAS positive lung cancers                                     2016:\                                                                                                                     0 new trials\
  (BIND Therapeutics)                                                                                                                                                                                                                                                                                              NCT02479178 (Ph II): Terminated\                                                                                           4 trials completed\
                                                                                                                                                                                                                                                                                                                   NCT02283320 (Ph II): Completed\                                                                                            Pfizer purchased BIND Therapeutics\' bankruptcy assets July 2016.[31](#btm210143-bib-0031){ref-type="ref"}
                                                                                                                                                                                                                                                                                                                   NCT01812746 (Ph II): Completed\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT01792479 (Ph II): Completed\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT01300533 (Ph I): Completed                                                                                              

  Cynviloq\                                             Paclitaxel polymeric micelle nanoparticle                                                                            Breast cancer                                                                                                                         2016:\                                                                                                                     0 new trials\
  IG‐001\                                                                                                                                                                                                                                                                                                          NCT02064829 (not provided): Completed                                                                                      1 trial completed
  (Sorrento)                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Genexol‐PM\                                           Paclitaxel polymeric micelle nanoparticle                                                                            Head and neck or breast cancer                                                                                                        2016:\                                                                                                                     2 new trials\
  (Samyang Biopharmaceuticals)                                                                                                                                                                                                                                                                                     NCT01689194 (Ph II): Unknown\                                                                                              1 trial completed\
                                                                                                                                                                                                                                                                                                                   NCT02263495 (Ph II): Completed\                                                                                            1 trial changed to unknown status
                                                                                                                                                                                                                                                                                                                   NCT00912639 (Ph IV): Unknown\                                                                                              
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT02739633 (Ph II): Recruiting NCT03008512 (Ph II): Recruiting                                                            

  NC‐6004 Nanoplatin\                                   Polyamino acid, PEG, and cisplatin derivative micellar nanoparticle                                                  Advanced solid tumors, lung, biliary, bladder, or pancreatic cancers                                                                  2016:\                                                                                                                     3 new trials\
  (Nanocarrier)                                                                                                                                                                                                                                                                                                    NCT02240238 (Ph I/II): Active, not recruiting\                                                                             1 trial changed to unknown status
                                                                                                                                                                                                                                                                                                                   NCT02043288 (Ph III): Unknown\                                                                                             
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03771820 (Ph II): Not yet recruiting\                                                                                   
                                                                                                                                                                                                                                                                                                                   NCT03109158 (Ph I): Completed\                                                                                             
                                                                                                                                                                                                                                                                                                                   NCT02817113 (Ph I): Unknown                                                                                                

  NC‐4016 DACH‐Platin micelle\                          Polyamino acid, PEG, and oxaliplatin micellar nanoparticle                                                           Advanced solid tumors or lymphomas                                                                                                    2016:\                                                                                                                     0 new trials
  (Nanocarrier)                                                                                                                                                                                                                                                                                                    NCT01999491 (Ph I): Completed                                                                                              

  NK105\                                                Paclitaxel micelle                                                                                                   Breast cancer                                                                                                                         2016:\                                                                                                                     0 new trials\
  (Nippon Kayaku)                                                                                                                                                                                                                                                                                                  NCT01644890 (Ph III): Completed                                                                                            1 trial completed

  Docetaxel‐PM\                                         Docetaxel micelle                                                                                                    Head and neck cancer and advanced solid tumors                                                                                        2016:\                                                                                                                     1 new trial\
  DOPNP201\                                                                                                                                                                                                                                                                                                        NCT02639858 (Ph II): Recruiting\                                                                                           1 trial completed
  (Samyang Biopharmaceuticals)                                                                                                                                                                                                                                                                                     NCT02274610 (Ph I): Completed\                                                                                             
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03585673 (Ph II): Recruiting                                                                                            

  CriPec\                                               Docetaxel micelles                                                                                                   Solid tumors, ovarian cancer                                                                                                          2016:\                                                                                                                     2 new trials\
  (Cristal Therapeutics)                                                                                                                                                                                                                                                                                           NCT02442531 (Ph I): Completed\                                                                                             1 trial completed
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03712423 (Ph I): Recruiting\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT03742713 (Ph II): Recruiting                                                                                            

  CRLX101\                                              Cyclodextrin‐based nanoparticle‐camptothecin conjugate                                                               Ovarian, renal cell, small cell lung, or rectal cancers                                                                               2016:\                                                                                                                     9 new trials (1 terminated, 1 withdrawn, 5 completed)\
  (Cerulean)                                                                                                                                                                                                                                                                                                       NCT02187302 (Ph II): Completed\                                                                                            2 previous trials completed\
                                                                                                                                                                                                                                                                                                                   NCT02010567 (Ph I/II): Active, not recruiting\                                                                             2 previous trials terminated\
                                                                                                                                                                                                                                                                                                                   NCT02389985 (Ph I): Terminated (company decision)\                                                                         NCT02010567 (Ph I/II): Addition of CRLX101 to standard chemoradiotherapy was in locally advanced rectal cancer patients demonstrated well‐tolerability.[32](#btm210143-bib-0032){ref-type="ref"}
                                                                                                                                                                                                                                                                                                                   NCT01803269 (Ph II): Terminated (due to lack of activity and slow accrual)\                                                
                                                                                                                                                                                                                                                                                                                   NCT01652079 (Ph II): Completed\                                                                                            
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT02769962 (Ph I): Recruiting\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT03531827 (Ph II): Recruiting\                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT02648711(Ph I): Terminated (company decision)\                                                                          
                                                                                                                                                                                                                                                                                                                   NCT01380769 (Ph II): Completed NCT01612546 (Ph II): Completed\                                                             
                                                                                                                                                                                                                                                                                                                   NCT00333502 (Ph II): Completed\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT01625936 (Ph I): Completed\                                                                                             
                                                                                                                                                                                                                                                                                                                   NCT00753740 (Ph II): Withdrawn (poor trial recruitment)\                                                                   
                                                                                                                                                                                                                                                                                                                   NCT00163319 (Ph III): Completed                                                                                            

  CRLX301\                                              Cyclodextrin based nanoparticle‐docetaxel conjugate                                                                  Dose escalation study in advanced solid tumors                                                                                        2016:\                                                                                                                     0 new trials\
  (Cerulean)                                                                                                                                                                                                                                                                                                       NCT02380677 (Ph I/II): Terminated (company decision)                                                                       1 trial terminated

  Polymeric and micelles (other)                                                                                                                                                                                                                                                                                                                                                                                                              

  RadProtect\                                           PEG, iron, and amifostine micelle\                                                                                   Dose escalation and safety for acute radiation syndrome                                                                               2016:\                                                                                                                     0 new trials
  (Original BioMedicals)                                Transferrin‐mediated chelation for amifostine release                                                                                                                                                                                                      NCT02587442 (Ph I): Unknown                                                                                                

  Albumin‐bound (cancer)                                                                                                                                                                                                                                                                                                                                                                                                                      

  ABI‐009\                                              Albumin bound rapamycin                                                                                              Bladder cancer, PEComa, or pulmonary arterial hypertension                                                                            2016:\                                                                                                                     12 new trials (2 completed)
  (Aadi with Celgene)                                                                                                                                                                                                                                                                                              NCT02009332 (Ph I/II): Recruiting\                                                                                         
                                                                                                                                                                                                                                                                                                                   NCT02587325 (Ph I): Recruiting\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT02494570 (Ph II): Active not recruiting\                                                                                
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03747328 (Ph II): Not yet recruiting\                                                                                   
                                                                                                                                                                                                                                                                                                                   NCT03657420 (Ph I): Not yet recruiting\                                                                                    
                                                                                                                                                                                                                                                                                                                   NCT03670030 (Ph II): Recruiting\                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03646240 (Ph I): Recruiting\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT03190174 (Ph I): Recruiting\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT00635284 (Ph I): Completed\                                                                                             
                                                                                                                                                                                                                                                                                                                   NCT03817515: Expanded access status: Available\                                                                            
                                                                                                                                                                                                                                                                                                                   NCT03439462 (Ph II): Recruiting\                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03463265 (Ph II): Recruiting\                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03660930 (Ph I): Recruiting\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT02975882 (Ph I): Recruiting\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT02646319 (Ph I): Completed                                                                                              

  ABI‐011\                                              Albumin bound thiocolchicine analog (IDN 5405)                                                                       Solid tumors or lymphomas                                                                                                             2016:\                                                                                                                     0 new trials
  (NantBioScience)                                                                                                                                                                                                                                                                                                 NCT02582827 (Ph I): Recruiting                                                                                             

  Inorganic (cancer)                                                                                                                                                                                                                                                                                                                                                                                                                          

  AuroLase\                                             PEG‐coated silica‐gold nanoshells for near infrared light facilitated thermal ablation                               Thermal ablation of solid primary and/or metastatic lung tumors                                                                       2016:\                                                                                                                     2 new trials (1 completed)\
  (Nanospectra Biosciences)                                                                                                                                                                                                                                                                                        NCT01679470 (not provided): Terminated\                                                                                    1 trial terminated
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT02680535 (not provided): Recruiting\                                                                                    
                                                                                                                                                                                                                                                                                                                   NCT00848042 (not provided): Completed                                                                                      

  NBTXR3\                                               Hafnium oxide nanoparticles stimulated with external radiation to enhance tumor cell death via electron production   Locally advanced squamous cell carcinoma                                                                                              2016:\                                                                                                                     Received CE mark approval in 2019\
  PEP503\                                                                                                                                                                                                                                                                                                          NCT01946867 (Ph I): Unknown\                                                                                               6 new trials\
  (Nanobiotix)                                                                                                                                                                                                                                                                                                     2019 additions:\                                                                                                           1 trial changed to unknown status
                                                                                                                                                                                                                                                                                                                   NCT02721056 (Ph II): Unknown\                                                                                              
                                                                                                                                                                                                                                                                                                                   NCT02805894 (Ph II): Recruiting\                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03589339 (Ph II): Not yet recruiting\                                                                                   
                                                                                                                                                                                                                                                                                                                   NCT02379845 (Ph II): Active not recruiting\                                                                                
                                                                                                                                                                                                                                                                                                                   NCT02901483 (Ph I): Recruiting\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT02465593 (Ph I): Recruiting                                                                                             

  Cornell Dots                                          Silica nanoparticles with a NIR fluorophore, PEG coating, and a ^124^I radiolabeled cRGDY targeting peptide          Imaging of melanoma and malignant brain tumors                                                                                        2016:\                                                                                                                     2 new trials
                                                                                                                                                                                                                                                                                                                   NCT01266096 (not provided): Active, not recruiting\                                                                        
                                                                                                                                                                                                                                                                                                                   2019 additions:\                                                                                                           
                                                                                                                                                                                                                                                                                                                   NCT03465618 (Ph I): Recruiting\                                                                                            
                                                                                                                                                                                                                                                                                                                   NCT02106598 (Ph II): Recruiting                                                                                            

  Magnablate                                            Iron nanoparticles                                                                                                   Thermal ablation for prostate cancer                                                                                                  2016:\                                                                                                                     0 new trials\
                                                                                                                                                                                                                                                                                                                   NCT02033447 (Ph 0): Completed                                                                                              1 trial completed
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note*: These trials are grouped by particle type and inidication. Modified with permission from Reference [1](#btm210143-bib-0001){ref-type="ref"}.

Abbreviations: EMA, European Medicines Agency; FDA, Food and Drug Administration.

4. NEW NANOPARTICLE TRIALS {#btm210143-sec-0004}
==========================

Since 2016, our search revealed 18 new nanoparticles to have entered clinical trials. Of these 18 nanoparticles, 12 are liposomes and 17 are indicated for cancer (15 being for treatment and 2 for imaging). The lone non‐cancer indication is mRNA‐1944, which are two mRNAs encoding heavy and light chains of anti‐Chikungunya antibody formulated in lipid nanoparticles, toward the prevention of Chikungunya virus infection. Table [3](#btm210143-tbl-0003){ref-type="table"} summarizes these findings. It should be noted that other clinical trials investigating nanoparticles for the delivery of mRNA exist but since they are predominately delivered through intradermal or other routes of administration they will not be covered here. We point the reader to a recent review on mRNA delivery strategies where current clinical trials and delivery vehicles are a primary focus.[19](#btm210143-bib-0019){ref-type="ref"}

###### 

Intravenous nanoparticle therapies and diagnostics which are not clinically approved and are currently undergoing clinical trials (not yet recruiting, recruiting, enrolling by invitation, or active)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name (company)                                                                        Particle type/drug                                                                                                                             Investigated application/indication                                                                                 Current [ClinicalTrials.gov](https://ClinicalTrials.gov) identifiers (phase)
  ------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------
  Liposomes (cancer)                                                                                                                                                                                                                                                                                                                                       

  MM‐310\                                                                               Nanoliposomal encapsulated docetaxel and functionalized with antibodies targeted to the EphA2 receptor                                         Solid tumors                                                                                                        NCT03076372 (Ph I): Recruiting
  (Merrimack Pharmaceuticals)                                                                                                                                                                                                                                                                                                                              

  EGFR(V)‐EDV‐Dox\                                                                      Bacterially derived minicell encapsulating doxorubicin                                                                                         Recurrent glioblastoma                                                                                              NCT02766699 (Ph I): Recruiting
  (EnGeneIC)                                                                                                                                                                                                                                                                                                                                               

  Alprostadil liposome\                                                                 Alprostadil liposome                                                                                                                           Safety and tolerability                                                                                             NCT03669562 (Ph I): Recruiting
  (CSPC ZhongQi Pharmaceutical Technology)                                                                                                                                                                                                                                                                                                                 

  Liposomal Annamycin\                                                                  Liposomal Annamycin                                                                                                                            Acute myeloid leukemia                                                                                              NCT03388749 (Ph II): Recruiting\
  (Moleculin Biotech)                                                                                                                                                                                                                                                                                                                                      NCT03315039 (Ph II): Recruiting

  FF‐10831\                                                                             Liposomal Gemcitabine                                                                                                                          Advanced solid tumors                                                                                               NCT03440450 (Ph I): Recruiting
  (Fujifilm Pharmaceuticals)                                                                                                                                                                                                                                                                                                                               

  Anti‐EGFR‐IL‐dox\                                                                     Doxorubicin‐loaded anti‐EGFR immunoliposomes                                                                                                   Advanced triple negative EGFR positive breast cancer\                                                               NCT02833766 (Ph II): Recruiting\
  (Swiss Group for Clinical Cancer Research; University Hospital, Basel, Switzerland)                                                                                                                                                  High grade gliomas                                                                                                  NCT03603379 (Ph I): Recruiting

  TLD‐1/Talidox\                                                                        A new formulation of liposomal doxorubicin                                                                                                     Advanced solid tumors                                                                                               NCT03387917 (Ph I): Recruiting
  (InnoMedica)                                                                                                                                                                                                                                                                                                                                             

  NC‐6300\                                                                              Micelle encapsulated epirubicin                                                                                                                Advanced solid tumors or soft tissue sarcoma                                                                        NCT03168061 (Ph II): Recruiting
  (NanoCarrier)                                                                                                                                                                                                                                                                                                                                            

  Liposomes (gene therapy: Cancer)                                                                                                                                                                                                                                                                                                                         

  MRT5201\                                                                              mRNA encapsulated in PEGylated liposomes                                                                                                       Ornithine transcarbamylase deficiency                                                                               NCT03767270 (Ph I): Not yet recruiting
  (Translate Bio)                                                                                                                                                                                                                                                                                                                                          

  Lipo‐MERIT\                                                                           Four naked ribonucleic acid (RNA)‐drug products formulated with liposomes                                                                      Cancer vaccine for advanced melanoma                                                                                NCT02410733 (Ph I): Recruiting
  (Biontech RNA Pharmaceuticals)                                                                                                                                                                                                                                                                                                                           

  Liposomes (immunotherapy: Cancer)                                                                                                                                                                                                                                                                                                                        

  IVAC_W\_bre1_uID                                                                      Patient‐specific liposome (specificity for antigen‐expression on a patient\'s tumor) complexed RNA                                             Triple negative breast cancer                                                                                       NCT02316457 (Ph I): Recruiting

  Liposomes (gene therapy: Vaccine)                                                                                                                                                                                                                                                                                                                        

  mRNA‐1944\                                                                            Two mRNAs that encode heavy and light chains of anti‐Chikungunya antibody formulated in Moderna\'s proprietary lipid nanoparticle technology   Safety, tolerability, pharmacokinetics and pharmacodynamics towards the prevention of Chikungunya virus infection   NCT03829384 (Ph I): Recruiting
  (Moderna)                                                                                                                                                                                                                                                                                                                                                

  Micelles (cancer)                                                                                                                                                                                                                                                                                                                                        

  MTL‐CEBPA\                                                                            Double stranded RNA formulated into SMARTICLES amphoteric liposomes                                                                            Advanced liver cancer                                                                                               NCT02716012 (Ph I): Recruiting
  (Mina alpha)                                                                                                                                                                                                                                                                                                                                             

  Imx‐110\                                                                              Micelle encapsulating a Stat3/NF‐kB/poly‐tyrosine kinase inhibitor and low‐dose doxorubicin                                                    Advanced solid tumors                                                                                               NCT03382340 (Ph I): Recruiting
  (Immix Biopharma Australia)                                                                                                                                                                                                                                                                                                                              

  IT‐141\                                                                               Micelle formulation of SN‐38                                                                                                                   Advanced cancer                                                                                                     NCT03096340 (Ph I): Recruiting
  (Intezyne Technologies)                                                                                                                                                                                                                                                                                                                                  

  Inorganic nanoparticles (cancer)                                                                                                                                                                                                                                                                                                                         

  NU‐0129\                                                                              Spherical nucleic acid platform consisting of nucleic acids arranged on the surface of a spherical gold nanoparticle                           Glioblastoma                                                                                                        NCT03020017 (Ph I): Active, not recruiting
  (Northwestern)                                                                                                                                                                                                                                                                                                                                           

  Nanoparticles for imaging applications                                                                                                                                                                                                                                                                                                                   

  AGuIX\                                                                                Polysiloxane Gd‐Chelates‐based nanoparticles                                                                                                   Advanced cervical cancer                                                                                            NCT03308604 (Ph I): Recruiting
  (National Cancer Institute, France)                                                                                                                                                                                                                                                                                                                      

  ONM‐100\                                                                              Micelle covalently conjugated to indocyanine green                                                                                             Intraoperative detection of cancer                                                                                  NCT03735680 (Ph II): Not yet recruiting
  (OncoNano Medicine)                                                                                                                                                                                                                                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note*: These trials and nanoparticles have appeared on the [ClinicalTrial.gov](https://ClinicalTrial.gov) database since 2016. Trials are grouped by particle type and indication.

5. CONCLUSIONS {#btm210143-sec-0005}
==============

Nanoparticle drug delivery systems offer many advantages over their free drug counterparts, can fundamentally change how therapeutics are delivered, and also enable the development of novel treatment modalities. This is demonstrated by the recent approvals of Patisiran/ONPATTRO (the first FDA approved RNAi therapeutic), VYXEOS (a nanoparticle capable of delivering synergistic ratios of two drugs), and NBTXR3/Hensify (a radio‐enhancing nanoparticle that synergizes with standard of care radiation oncology treatments). On the other hand, nanoparticles also face unique challenges related to their biological, technological, and clinical limitations that must be addressed to achieve consistent clinical impact. These advantages and challenges were discussed in‐depth in the 2016 review[1](#btm210143-bib-0001){ref-type="ref"} and in many other reviews.[20](#btm210143-bib-0020){ref-type="ref"}, [21](#btm210143-bib-0021){ref-type="ref"}, [22](#btm210143-bib-0022){ref-type="ref"}, [23](#btm210143-bib-0023){ref-type="ref"}, [24](#btm210143-bib-0024){ref-type="ref"}, [25](#btm210143-bib-0025){ref-type="ref"} With the increasing numbers of nanoparticle clinical trials, including nanoparticle technologies that were in trials at the time of our previous article (Table [2](#btm210143-tbl-0002){ref-type="table"}) and those that have entered the clinic since then (Table [3](#btm210143-tbl-0003){ref-type="table"}), the interest and pursuit of successful nanoparticle technologies continues. Taken together with these recent approvals, the field of nanoparticle drug delivery continues to make breakthroughs that improve human health.
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